Product information and disease description Product description Product information Drug/Drug, drug/disease interactions

Effects of other drugs on LB-102

6 evidence topics · 5 sources

Company statement on expected drug interactions

“No expected food effect or DDIs” (opens the source at this quote in a new tab)

NOVA-1 protocol: prohibited CYP2D6 inhibitors and CYP3A4 inhibitors and inducers

“Table 6.3 below provides a select list of CYP2D6 inhibitors and CYP3A4 inhibitors and inducers that are prohibited within 14 days of randomization and for the duration of the trial.” (opens the source at this quote in a new tab)

NOVA-1 protocol: prohibited antipsychotics and other psychotropic medications

“Patients who are currently taking oral antipsychotic medications, monoamine oxidase inhibitors (MAOIs), anticonvulsants (e.g., lamotrigine, Depakote), tricyclic antidepressants (e.g., imipramine, desipramine), selective serotonin reuptake inhibitors, and any other antidepressants or any other psychoactive medications (except lorazepam, zolpidem, zaleplon, eszopiclone, or similar benzodiazepines, diphenhydramine, benztropine, and propranolol).” (opens the source at this quote in a new tab)

Alcohol, cannabis, and smoking

“Participants were not permitted to smoke, consume alcohol, cannabis, or illicit substances, so pharmacologic interactions with these substances were not evaluated.” (opens the source at this quote in a new tab)

Class context: metabolism and transport of amisulpride

“In vitro, amisulpride was not a substrate of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4.” (opens the source at this quote in a new tab)
“Amisulpride is a substrate for P-gp, BCRP, OCT1, MATE1 and MATE2-K, but not a substrate for OATP1B1, OATP1B3, OAT1, OAT3 and OCT2.” (opens the source at this quote in a new tab)
“No clinical drug interaction trials have been conducted with BARHEMSYS.” (opens the source at this quote in a new tab)

“Co-administration of amisulpride and clozapine may lead to an increase in plasma levels of amisulpride” (opens the source at this quote in a new tab)

Class context: QT-prolonging drugs in amisulpride labeling

“To avoid potential additive effects, avoid use of BARHEMSYS in patients taking droperidol.” (opens the source at this quote in a new tab)
“ECG monitoring is recommended in patients taking other drugs known to prolong the QT interval (e.g., ondansetron)” (opens the source at this quote in a new tab)

“Caution is advised when prescribing amisulpride with medicines known to prolong the QT interval, e.g., class IA antiarrythmics (e.g., quinidine, disopyramide) and class III antiarrythmics (e.g. amiodarone, sotalol), some antihistaminics, some other antipsychotics and antimalarials (e.g., mefloquine) (see section 4.4)” (opens the source at this quote in a new tab)

Clinical drug interaction studies with LB-102

No evidence found.

In vitro CYP and transporter substrate findings for LB-102

No evidence found.

Restrictions on QT-prolonging medications in the LB-102 trial protocols

No evidence found.